Answers are grounded in this paper and cite their sources.
We demonstrate that EGFR is a relevant immunotherapeutic target in TNBC, and EGFR CAR-T exhibits potent and specific antitumor activity against TNBC, suggesting the potential of this third-generation EGFR CAR-T as an immunotherapy tool to treat TNBC in the clinic.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: